Appetitive Conditioning in Anorexia Nervosa (ACAN)

March 23, 2026 updated by: Centre for Addiction and Mental Health

Appetitive Conditioning in Anorexia Nervosa: Neural, Physiological, and Behavioral Mechanisms

Anorexia nervosa (AN) is characterized by a reduced drive to pursue rewarding experiences and stimuli. Food consumption - which is almost universally experienced as pleasurable - is not described as rewarding by those with AN. This is thought to be underpinned by abnormalities around reward learning. However, the most fundamental question relating to reward in AN - whether those with AN may learn positive associations - remains unaddressed.

In this study, the investigators will identify the patterns of how those with AN acquire positive associations, how they diminish, and their relationships to physiology (heart rate and pupil responses) and brain activation. In assessing the robustness of this learning, the investigators will investigate the extent to which this association is reactivated after 24 hours, and the extent to which a memory prompt will help reinstate this previously learned positive association.

This project will allow for important advances in our understanding of the neurobiology of AN. The investigators will first identify if, and how, those with AN come to learn positive associations to cues, and secondly, the extent to which learned positive associations remain over time. Moreover, the investigators will use machine learning to ascertain whether reward learning can be predicted by physiological and neural biomarkers.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Individuals with anorexia nervosa (AN) suffer from anxiety, reduced pleasure from normally rewarding situations (anhedonia), and disturbed body image. However, restriction of calories from their morbid fear of weight gain, resulting in starvation, typically brings them to attention and has been the primary focus of most treatments and many research studies. Yet, treatments have largely been inadequate, with remission rates less than 25%. Anhedonia and disturbances in reward may be important targets of new treatment approaches. Those with AN report little pleasure in food consumption, social domains, and pursuit of novelty and fun. Neuroimaging studies demonstrate disturbances in reward circuits in response to food- and body-related stimuli and monetary rewards, but results are inconsistent. This may be due to confounding effects of anxiety triggered by symptom-related stimuli. Further, a fundamental process of the overall reward response that has not been studied in AN is reward learning - how one's brain learns to associate stimuli with the experience of reward ("appetitive Pavlovian conditioning"). To investigate this, the investigators will enroll 30 underweight individuals with AN, 30 with weight-restored AN, and 30 healthy controls ages 12-22 to perform a reward conditioning paradigm. The investigators will use infant laughter, a social reward with robust effects that is unlikely to be confounded by other co-occurring symptoms. To understand associated neural activity and physiological responses, the investigators will perform conditioning and examine reinstatement 24-hours later, while obtaining functional magnetic resonance imaging, heart rate deceleration, and pupil dilation data, in addition to subjective degrees of positive experience. Data from underweight and weight-restored AN will further allow us to probe starvation state-related effects. Results will advance our understanding of how reward stimuli are learned and the associated aberrant neural or physiological markers. This will yield a comprehensive mechanistic understanding of hedonic functioning in AN to rationally inform future novel treatment development.

Study Type

Observational

Enrollment (Estimated)

90

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M6J 1H3
        • Centre for Addiction and Mental Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years to 22 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Investigators will enroll 90 female participants between the ages of 12 and 22 (30 with current anorexia nervosa - restricting type, 30 with a history of anorexia nervosa - restricting type, and 30 non-clinical healthy controls).

Description

Inclusion Criteria:

  1. AN-Restricting (AN-R) Group

    Inclusion criteria:

    1. Females from any racial or ethnic background
    2. Ages between 12 and 22 years
    3. Meet DSM-5 criteria for AN - restricting subtype
    4. Medically stable designated by their physician in the past month (having any of the following measurements taken by a physician or nurse within the past month preceding the telephone screen: (i) orthostasis: drop in systolic blood pressure > 20 mm Hg or diastolic blood pressure > 10 mm Hg, or an increase in heart rate (HR) > 20 bpm upon standing for 3 minutes after lying down; (ii) resting HR <45; or (iii) resting blood pressure of <80 mm Hg systolic or <50 mm Hg diastolic 99. Prospective participants who do not meet the medical instability criteria and otherwise pass the telephone screen, will be invited to proceed to the consent process. If they have not had these measurements done in the month prior, we will encourage them to visit their doctor or nurse to have these done and then to recontact us with the results ):
    5. BP and pulse measured at the day of the scan by the investigators

      • Heart rate ≥ 45 at rest
      • Resting blood pressure of ≥80 mm Hg systolic and ≥50 mm Hg diastolic
      • Lying and standing (after 3 min.) BP drop of ≤20 systolic and ≤10 diastolic and increase in HR ≤20 bpm
    6. Not taking psychiatric medications or taking serotonin-reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor medications at stable doses
  2. History of AN-Restricting Group:

    Inclusion criteria:

    1. Females from any racial or ethnic background
    2. Ages between 12 and 22 years
    3. EDE-Q ≤ 2 (puts them within 1 standard deviation [SD] of community norms and lower than 1 SD from clinical norms for female AN-R)
    4. History of AN - meeting full criteria, diagnosed by a licensed clinician
    5. Not taking psychiatric medications or taking serotonin-reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor medications at stable doses
  3. Healthy controls:

Inclusion criteria:

  1. Healthy females from any racial or ethnic background
  2. Ages 12-22 years

Exclusion Criteria:

  • AN-R and History of AN-R groups:

    1. Antipsychotic medications
    2. Change in dose of psychotropic medication over the previous 4 weeks
    3. Current psychotic disorder

Healthy controls:

  1. Any current Axis I disorder
  2. Eating Disorder Examination Questionnaire score greater than established community norms (>2)
  3. Met criteria for AN (in the past or present)

All:

  1. Neurological disorder
  2. Infants or children of their own
  3. Pregnancy
  4. Current risk of suicide with a plan and intent
  5. Ferromagnetic metal implantations or devices (electronic implants or devices, infusion pumps, aneurysm clips, metal fragments or foreign bodies, metal prostheses, joints, rods or plates)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
AN-Restricting (AN-R)
Meet Diagnostic and Statistical Manual (DSM-5) criteria for anorexia nervosa, restricting subtype
The investigators will examine acquisition and extinction of learned associations to positively-valenced, socially rewarding yet symptom-neutral infant laughter sounds in an appetitive conditioning paradigm. The investigators will also examine spontaneous recovery of this association 24 hours later when re-presented with these cues, and the reinstatement of this association when re-exposed to infant laughter.
Weight Restored AN-Restricting (WRAN-R)
  • History of anorexia nervosa, restricting type - previously meeting full DSM-5 criteria.
  • Eating Disorder Examination Questionnaire (EDE-Q) ≤ 2 (within 1 standard deviation [SD] of community norms and lower than 1 standard deviation from clinical norms for female anorexia nervosa, restricting type populations)
The investigators will examine acquisition and extinction of learned associations to positively-valenced, socially rewarding yet symptom-neutral infant laughter sounds in an appetitive conditioning paradigm. The investigators will also examine spontaneous recovery of this association 24 hours later when re-presented with these cues, and the reinstatement of this association when re-exposed to infant laughter.
Healthy controls
Healthy females from any racial or ethnic background, not meeting DSM-5 criteria for any psychiatric disorder.
The investigators will examine acquisition and extinction of learned associations to positively-valenced, socially rewarding yet symptom-neutral infant laughter sounds in an appetitive conditioning paradigm. The investigators will also examine spontaneous recovery of this association 24 hours later when re-presented with these cues, and the reinstatement of this association when re-exposed to infant laughter.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Positive valence
Time Frame: Day 1
A 10-point Likert scale will assess self-reported pleasantness and arousal for each conditioned stimulus, and unconditioned stimulus expectancy
Day 1
Positive valence
Time Frame: Day 2
A 10-point Likert scale will assess self-reported pleasantness and arousal for each conditioned stimulus, and unconditioned stimulus expectancy
Day 2
Pupillary dilation
Time Frame: Day 1
Measured with an eye-tracking camera
Day 1
Pupillary dilation
Time Frame: Day 2
Measured with an eye-tracking camera
Day 2
Heart rate deceleration
Time Frame: Day 1
Measured with an electrocardiogram
Day 1
Heart rate deceleration
Time Frame: Day 2
Measured with an electrocardiogram
Day 2
Brain activation
Time Frame: Day 1
Neural activation in reward circuits measured with functional magnetic resonance imaging
Day 1
Brain activation
Time Frame: Day 2
Neural activation in reward circuits measured with functional magnetic resonance imaging
Day 2

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jamie D Feusner, M.D., Centre for Addiction and Mental Health
  • Principal Investigator: Stuart Murray, Ph.D., University of Southern California

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 30, 2022

Primary Completion (Actual)

December 25, 2025

Study Completion (Estimated)

June 30, 2026

Study Registration Dates

First Submitted

August 30, 2022

First Submitted That Met QC Criteria

September 2, 2022

First Posted (Actual)

September 8, 2022

Study Record Updates

Last Update Posted (Actual)

March 27, 2026

Last Update Submitted That Met QC Criteria

March 23, 2026

Last Verified

November 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anorexia Nervosa

Clinical Trials on appetitive conditioning

Subscribe